Module contents

Module home

Module introduction

Module information

About the authors

Pre-module test

 

Section 1: Brain structure and function

(1.1) Section 1: Brain structure and function

(1.2) Interactive exercise: neuroimaging techniques

(1.3) Brain volume

(1.4) Changes with abstinence

(1.5) Reflection

(1.6) Wernicke’s encephalopathy and Korsakoff’s syndrome

(1.7) Wernicke’s encephalopathy and Korsakoff’s syndrome

(1.8) Section 1: Recap

(1.9) Section 1: Summary

 

Section 2: The neurocircuitry of alcohol addiction

(2.1) Section 2: The neurocircuitry of alcohol addiction

(2.2) The neurocircuitry of alcohol addiction

(2.3) Early stages of addiction

(2.4) Addiction

(2.5) Brain regions important for addiction

(2.6) Functional MRI

(2.7) Interactive exercise: cue exposure studies

(2.8) Interactive exercise: cue exposure studies continued

(2.9) Effect of medication on cue exposure and craving

(2.10) Decision making

(2.11) Reward processing

(2.12) Section 2: Recap

(2.13) Section 2: Summary

 

Section 3: Pharmacology

(3.1) Section 3: Pharmacology

(3.2) How alchohol interacts with the brain

(3.3) How alchohol interacts with the brain

(3.4) Neuroimaging brain function

(3.5) Rewarding effects of alcohol: role of dopamine and opioid systems

(3.6) Interactive exercise: neuroimaging studies

(3.7) Rewarding effects of alcohol: the role of dopamine and modulators

(3.8) Regulation of the dopaminergic reward pathway: opioidergic neurotransmission

(3.9) Reflection

(3.10) Regulation of the dopaminergic reward pathway: opioidergic neurotransmission

(3.11) Section 3: Recap

(3.12) Section 3: Summary

 

Section 4: Pharmacology continued

(4.1) Section 4: Pharmacology continued

(4.2) What has neuroimaging told us about the opioid system?

(4.3) What have genetic studies told us about the opioid system?

(4.4) Serotonin (5HT)

(4.5) The effect of acute alcohol on serotonergic neurotransmission

(4.6) Clinical implications

(4.7) What have neuroimaging and genetic studies told us about the serotonergic system?

(4.8) Interactive exercise: GABA receptors

(4.9) GABA-A receptors

(4.10) What has neuroimaging told us about the GABA-benzodiazepine system?

(4.11) Pharmacological challenges

(4.12) What have genetic studies told us about the gabaergic system?

(4.13) NMDA receptors

(4.14) The effect of acute alcohol on glutamatergic neurotransmission

(4.15) The effect of chronic alcohol on glutamatergic neurotransmission

(4.16) Withdrawal

(4.17) Cannabinoid receptors

(4.18) The effect of acute alcohol on cannabinoid neurotransmission

(4.19) What has neuroimaging told us about the cannabinoid system?

(4.20) Section 4: Recap

(4.21) Section 4: Summary

 

Section 5: Pharmacotherapies for alcohol addiction

(5.1) Section 5: Pharmacotherapies for alcohol addiction

(5.2) Benzodiazepines

(5.3) Disulfiram

(5.4) Disulfiram

(5.5) Acamprosate

(5.6) Naltrexone and nalmefene

(5.7) Interactive exercise: other non-licensed medication in use and potential future therapies

(5.8) Interactive exercise: pharmacotherapies

(5.9) Summary table of pharmacotherapeutic effects

(5.10) Section 5: Recap

(5.11) Section 5: Summary

 

Module summary

Module summary I

Module summary II

Module test

Acknowledgements

Send feedback

 

Useful resources

Take-home notes

References

Further reading

 

 

© 2020 Royal College of Psychiatrists